Menu Close

New Alzheimer’s drug shines light on need for assessments to head off ‘a tsunami of cognitive afflictions’

Two stories dominated Alzheimer’s news this year: The FDA’s approval of Leqembi, the first drug to slow progression of the disease, and a surprising study showing that mild cognitive impairment is wildly underdiagnosed.